A Tale of Two Models

The real story here is not the vibe check, it is the diversification tell. Anthropic building its own drug discovery arm looks less like a side project and more like a hedge, since if the model layer commoditizes and every lab's good enough tier blurs together, owning a vertical application gives you a moat and a second story for the IPO roadshow. Watch whether selling shovels to pharma becomes the template other labs copy once they realize chatbot supremacy is not a permanent asset.